AVE8062: A new combretastatin derivative vascular disrupting agent

Expert Opinion on Investigational Drugs

Volumn 18, Issue 10, 2009, Pages 1541-1548

  Delmonte, Angelo ^a   Sessa, Cristiana ^a,b,c  

^a OSPEDALE SAN GIOVANNI   (Switzerland)

^b ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^c REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

Angiogenesis; Antivascular disrupting agents; New drugs; Solid tumor

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOCETAXEL; DRUG METABOLITE; IFOSFAMIDE; N ACETYLCOLCHINOL PHOSPHATE; OXALIPLATIN; PLACEBO; RPR 258063A; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ASTHENIA; BONE MARROW TOXICITY; BRAIN ISCHEMIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL TRIAL; COLON ADENOCARCINOMA; COLON CANCER; DOSE RESPONSE; DRUG CLEARANCE; DRUG CYTOTOXICITY; DRUG DOSE INCREASE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FEBRILE NEUTROPENIA; HEADACHE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CANCER; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVARY CANCER; RECOMMENDED DRUG DOSE; RECTUM CANCER; REPEATED DRUG DOSE; REVIEW; SIDE EFFECT; SOFT TISSUE SARCOMA; SOLID TUMOR; THORAX PAIN; THROMBOCYTOPENIA; TUMOR BLEEDING; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VOCAL CORD PARALYSIS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; SERINE; STILBENES; TUBULIN;

EID: 70349338935     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543780903213697     Document Type: Review

References (40)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70
2. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-420
3. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-435
4. Sorbera LA, Leeson PA, Bayès M. Bevacizumab oncolytic. Drugs Future 2002;27:625-632
5. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-4655 (Pubitemid 34898591)
6. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002;99:11393-11398 (Pubitemid 34920936)
7. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-427 (Pubitemid 38173977)
8. Hinnen P, Falms E. Vascular disrupting agents in clinical developments. Br J Cancer 2007;96:1159-1165 (Pubitemid 46625071)
9. Siemann DW, Chaplin DJ, Horsman MR. Vascular-targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-2499 (Pubitemid 38715753)
10. Kakolyris S, Fox S, Koukourakis M, et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br J Cancer 2000;82:844-851 (Pubitemid 30085237)
11. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer 2001;84:1354-1362 (Pubitemid 32522104)
12. Dark GD, Sally A, Vivien E, et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Res 1997;57:1829-1834
13. Kanthou C, Tozer GM. The tumoral vascular targeting agent Combretastatin-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99:2060-2069 (Pubitemid 34525489)
14. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shutdown induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-6422
15. Milosevic MF, Fyles AW, Hill RP. The relationship between elevated interstitial fluid pressure and blood flow in tumors: a bioengineering analysis. Int J Radiat Oncol Biol Phys 1999;43:1111-1123
16. Lominadze D, Mchediishvili G. Red blood cell behavior at low flow rate in microvessels. Microvasc Res 1999;58:187-189 (Pubitemid 29419945)
17. Prise VE, Honess DJ, Stratford MRL, et al. The vascular response of tumor and normal tissues in the rat to the vascular targeting agent, combretastatin A-4-phosphate, at clinical relevant doses. Int J Oncol 2002;21:717-726
18. Alexander JS, Hechtman HB, Shepro D. Serotonin induced actin polymerization and association with cytoskeletal elements in cultured bovine aortic endothelium. Biochem Biophys Res Commun 1987;143:152-158 (Pubitemid 17030478)
19. Brooks AC, Kanthou C, Cook IH, et al. The vascular targeting agent combretastatin A-4-phosphate induces neutrophils recruitment to endothelial cells in vitro. Anticancer Res 2003;23:3199-3206 (Pubitemid 36975414)
20. Parkins CS, Holder AJ, Hill SA, et al. Determinants of antivascular action by combretastatin A-4-phosphate: role of nitric oxide. Br J Cancer 2000;83:811-816 (Pubitemid 30694491)
21. Hori K, Saito S, Nihei Y, et al. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of novel combretastatin A-4 derivative, AC7700. Jpn J Cancer Res 1999;90:1026-1038 (Pubitemid 29500444)
22. Chiron MF, Attenot F, Lefranc C, et al. Effects of the tumor vasculature targeting agent, AVE8062A, on endothelial cells in vitro and in vivo. 94th AACR meeting, Washington, July 11-14, 2003; abstract 4878
23. Guffroy M, Dally C, Vrignaud P, et al. Evaluation of tissue perfusion (tumor, spleen, heart) in mice after administration of AVE8062, a tumor vascular-targeting agent. 95th AACR meeting, Orlando, March 2004; abstract 4699
24. Guffroy M, Dally C, Vrignaud P, et al. The tumor vascular-targeting agent AVE8062 induces tumor blood flow shut down and necrosis in an orthotopic model of colon cancer in mice. 96th AACR annual meeting, Anaheim, CA, 16 - 20 April 2005; abstract 3412
25. Lejeune P, Hodge T, Vrignaud P, Bissery M-C. In vivo antitumor activity and tumor necrosis induced by AVE8062A, a tumor vasculature targeting agent. 93rd AACR meeting, San Francisco, April 6-10, 2002; abstract 781
26. Hori K, Sato S. Microvascular mechanism by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003;89:1334-1344 (Pubitemid 37363426)
27. Jouannot E, Carrez C, Lassau N, et al. Demonstration in animal and human of AVE8062-induced tumor blood flow shutdown using dynamic contrast enhanced-ultrasonography (DCE-US). 98th AACR Annual Meeting. Los Angeles, CA, 14-18 April 2007; abstract LB-328
28. Lavisse S, Lejeune P, Rouffiac V, et al. Early quantitative evaluation of a tumor vasculature disruptive agent AVE8062A using dynamic contrast-enhanced ultrasonography. Invest Radiol 2008;43(2):100-111
29. Bissery M-C, Lejeune P, Vrignaud P. In vivo evaluation of AVE8062A, a compound active on the tumor vasculature. 93rd AACR meeting, San Francisco, 6 - 10 April 2002; abstract 780
30. Nihei Y, Suga Y, Morinaga Y, et al. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors. Jpn J Cancer Res 1999;90:1016-1025 (Pubitemid 29500443)
31. Lejeune P, Hodge T, Vrignaud P, et al. In vivo antitumor activity and tumor necrosis induced by AVE8062A, a tumor vasculature targeting agent. 93rd AACR Meeting; 2002
32. Bissery M-C, Lejeune P, Vrignaud P. In vivo synergy between platinum and AVE8062A, a tumor vasculature targeting agent. 94th AACR meeting, Washington, July 11-14, 2003; abstract 4877
33. Lejeune P, Vrignaud P, Goulaouic H, et al. In vivo synergy between docetaxel and AVE8062A, a tumor vasculature targeting agent. 96th AACR annual meeting, Anaheim, CA, 16 - 20 April 2005;46:abstract 3425
34. Kim TJ, Ravoori M, Landen CN, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res 2007;67:9337-9345 (Pubitemid 47535923)
35. Archimbaud Y, Fraschini MC, Pellerin R, et al. Mouse plasma and tumor pharmacokinetics of AVE8062 a new combretastatine. 93rd AACR meeting, San Francisco, 6 - 10 April 2002; abstract 779
36. Tolcher AW, Forero L, Celio P, et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8052A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days. Proc Am Soc Clin Oncol 2003;22:abstract 834
37. Soria JC, Sessa C, Perotti A, et al. A comprehensive study of translational research and safety exploration of the vascular disrupting agent (VDA) AVE8062 in combination with cisplatin administered every 3 weeks to patients with advanced solid tumors. 99th AACR Annual Meeting; San Diego, CA, 12 - 16 April 2008; abstract 07-11
38. Sessa C, Soria JC, Tolcher A, et al. A phase I safety, pharmacokinetic and pharmacodynamic study of AVE8062, a novel vascular disrupting agent, in patients with advanced solid tumors 7th TAT meeting, Amsterdam, 18 - 22 April 2009: abstract O36
39. Beerepoot LV, Radema SA, Witteveen EO, et al. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors. J Clin Oncol 2006;24:1491-1498
40. LoRusso PM, Gadgeel SM, Wozniak A, et al. Phase I clinical evaluation of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 2008;26:159-167